Stem cells are unspecialized cells that mature into specialised cells that comprise various types of tissue in the human body. They are distinguished by their ability to regenerate themselves through mitotic cell division and differentiate into a wide variety of specialised cell types. They are essential for the growth, maintenance, and repair of brains, bones, muscles, nerves, blood, skin, and other organs. Stem cells can be present throughout all phases of human development and at the end of life. Stem cell research has enormous promise for the discovery of new treatments for a wide range of critical illnesses and injuries.
Some stem cell-based therapies, such as hematopoietic stem cell transplants for leukaemia and epithelial stem cell-based treatments for burns and corneal diseases, have become clinical standards of care. Because of improvements in stem cell research, the breadth of prospective stem cell-based therapeutics has grown in recent years. People with spinal cord injuries, type 1 diabetes, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, heart disease, stroke, burns, cancer, and osteoarthritis may benefit from stem cell therapy.They may be employed in the future to replace cells and tissues that have been damaged or destroyed as a result of illness.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Stem Cell Manufacturing Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Stem Cell Manufacturing Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
The segmentation coverage of the study is provided below.
Stem Cell Manufacturing Market based on Product:
- Consumables
- Culture Media
- Other Consumables
- Instruments
- Bioreactors and Incubators
- Cell Sorters
- Other Instruments
- Stem Cell Lines
- Hematopoietic Stem Cells (HSC)
- Mesenchymal Stem Cells (MSC)
- Induced Pluripotent Stem Cells (iPSC)
- Embryonic stem Cells (ESC)
- Neural Stem Cells (NSC)
- Multipotent Adult Progenitor Stem Cells
Stem Cell Manufacturing Market based on Application:
- Research Applications
- Life Science Research
- Drug Discovery and Development
- Clinical Application
- Allogenic Stem Cell Therapy
- Autologous Stem Cell Therapy
- Cell and Tissue Banking Applications
Stem Cell Manufacturing Market based on End User:
- Pharmaceutical and Biotechnology Companies
- Academic Institutes
- Research Laboratories and Contract Research Organizations
- Hospitals and Surgical Centers
- Cell and Tissue banks
- Others
Stem Cell Manufacturing Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Based on kind, the stem cell treatment market is divided into allogeneic and autologous stem cell therapies. The allogeneic stem treatment category held the greatest market share in 2022. Various causes, such as less obstacles connected with stem cell generation and manufacturing, are driving greater demand for allogenic stem cells.
The stem cell treatment market is divided into four segments based on cell source: adipose tissue-derived MSCs, placental/umbilical cord-derived MSCs, bone marrow-derived MSCs, and other sources. The adipose tissue-derived stem cells segment led stem cell treatment in 2022, owing to the increasing use of these MSCs across many therapeutic applications. Additionally, greater research and implementation of placental cord-derived stem cells is expected to boost market growth in the future years.
The worldwide stem cell treatment market is divided into therapeutic applications such as musculoskeletal disorders, cardiovascular illnesses, wounds and surgeries, neurological disorders, inflammatory & autoimmune diseases, and others. In 2022, the therapeutic application sector for musculoskeletal ailments produced the most income. The increasing frequency of musculoskeletal illnesses such as osteoarthritis, as well as the increasing need for regenerative medicine in orthopaedic and sports medicine applications, are some of the primary reasons driving sector expansion.
- This report illustrates the most vital attributes of the Stem Cell Manufacturing Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Stem Cell Manufacturing Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Stem Cell Manufacturing Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Stem Cell Manufacturing Market.
List of Tables
TABLE 1. STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 2. STEM CELL MANUFACTURING MARKET VALUE FOR Consumables, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. STEM CELL MANUFACTURING MARKET VALUE FOR Instruments, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. STEM CELL MANUFACTURING MARKET VALUE FOR Stem Cell Lines, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 6. STEM CELL MANUFACTURING MARKET VALUE FOR Research Applications, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. STEM CELL MANUFACTURING MARKET VALUE FOR Clinical Application, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. STEM CELL MANUFACTURING MARKET VALUE FOR Cell and Tissue Banking Applications, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 10. STEM CELL MANUFACTURING MARKET VALUE FOR Pharmaceutical and Biotechnology Companies, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. STEM CELL MANUFACTURING MARKET VALUE FOR Academic Institutes, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. STEM CELL MANUFACTURING MARKET VALUE FOR Research Laboratories and Contract Research Organizations, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. STEM CELL MANUFACTURING MARKET VALUE FOR Hospitals and Surgical Centers, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. STEM CELL MANUFACTURING MARKET VALUE FOR Cell and Tissue banks, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 15. STEM CELL MANUFACTURING MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. NORTH AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 20. U.S STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. U.S STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 22. U.S STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 23. CANADA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 24. CANADA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 25. CANADA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. MEXICO STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. MEXICO STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. MEXICO STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. EUROPE STEM CELL MANUFACTURING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 30. EUROPE STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 31. EUROPE STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 32. EUROPE STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 33. GERMANY STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. GERMANY STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. GERMANY STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 36. U.K STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 37. U.K STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 38. U.K STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 39. FRANCE STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 40. FRANCE STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 41. FRANCE STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 42. ITALY STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. ITALY STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 44. ITALY STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 45. SPAIN STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 46. SPAIN STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 47. SPAIN STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ROE STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ROE STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. ROE STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. ASIA PACIFIC STEM CELL MANUFACTURING MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 55. CHINA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 56. CHINA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 57. CHINA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 58. INDIA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 59. INDIA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. INDIA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 61. JAPAN STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 62. JAPAN STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 63. JAPAN STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 64. REST OF APAC STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 67. LATIN AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 70. BRAZIL STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 73. ARGENTINA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 76. MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 79. SAUDI ARABIA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 82. UAE STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 83. UAE STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 84. UAE STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 85. REST OF MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA STEM CELL MANUFACTURING MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 88. THERMO FISHER SCIENTIFIC, INC. : FINANCIALS
TABLE 89. THERMO FISHER SCIENTIFIC, INC. : PRODUCTS & SERVICES
TABLE 90. THERMO FISHER SCIENTIFIC, INC. : RECENT DEVELOPMENTS
TABLE 91. ABBVIE INC.: FINANCIALS
TABLE 92. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 93. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 94. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 95. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 96. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 97. ASTELLAS PHARMA INC. : FINANCIALS
TABLE 98. ASTELLAS PHARMA INC. : PRODUCTS & SERVICES
TABLE 99. ASTELLAS PHARMA INC. : RECENT DEVELOPMENTS
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 102. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 103. ANTEROGEN.CO. LTD.: FINANCIALS
TABLE 104. ANTEROGEN.CO. LTD.: PRODUCTS & SERVICES
TABLE 105. ANTEROGEN.CO. LTD.: RECENT DEVELOPMENTS
TABLE 106. FUJIFILM CELLULAR DYNAMICS INC. : FINANCIALS
TABLE 107. FUJIFILM CELLULAR DYNAMICS INC. : PRODUCTS & SERVICES
TABLE 108. FUJIFILM CELLULAR DYNAMICS INC. : DEVELOPMENTS
TABLE 109. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 110. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 111. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 112. MERCK KGAA: FINANCIALS
TABLE 113. MERCK KGAA: PRODUCTS & SERVICES
TABLE 114. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 115. RHEACELL GMBH AND CO. KG: FINANCIALS
TABLE 116. RHEACELL GMBH AND CO. KG: PRODUCTS & SERVICES
TABLE 117. RHEACELL GMBH AND CO. KG: RECENT DEVELOPMENTS
